stockrowAMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) Net income
AMNEAL PHARMACEUTICALS, INC.'s net income for fiscal 2025 was $127.9M, compared with −$73.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was $209.5M. Over the past ten years it has ranged from −$603.6M (fiscal 2019) to $209.4M (fiscal 2016); the current reading is higher than 82% of that period. AMNEAL PHARMACEUTICALS, INC. ranks 11th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $127.9M | — |
| FY2024 | −$73.9M | — |
| FY2023 | −$48.7M | — |
| FY2022 | −$254.8M | — |
| FY2021 | $20.2M | (70.59%) |
| FY2020 | $68.6M | — |
| FY2019 | −$603.6M | — |
| FY2018 | −$201.3M | — |
| FY2017 | $169.3M | (19.15%) |
| FY2016 | $209.4M | 437.03% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $12.3M | (82.32%) |
| Jun 2026 | $69.6M | (10.75%) |
| Mar 2026 | $78.0M | 57.34% |
| Dec 2025 | $49.6M | 173.40% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| SUPN Indivior Pharmaceuticals Inc. compare | $450.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $273.0M |
| LNTH Lantheus Holdings, Inc. compare | $269.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. | $209.5M |
| LQDA Liquidia Corporation compare | $138.6M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $109.6M |
| ALKS Alkermes plc compare | −$351.0K |
| HIMS Hims & Hers Health, Inc. compare | −$142.0M |
| ELAN Elanco Animal Health Incorporated compare | −$199.0M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on AMRX
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement